larsucosterol
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 21, 2019 (NCT03837743)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
DNMT3B inhibitor
DNMT3A inhibitor
- DNA (cytosine-5)-methyltransferase 1INHIBITOR
DNMT1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](OS(=O)(=O)O)CC[C@]4(C)[C@H]3CC[C@]12C- Mol. weight
- 482.73 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802158 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04563026 | Phase 2 | Oct 31, 2020 | CTI Clinical Trial and Consulting Services, Durect |
| NCT03917407 | Phase 2 | Jul 1, 2019 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of Louisville |
| NCT03837743 | Phase 2 | Feb 21, 2019 | Durect, Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Durect | For profit | 2 | 1 | 1 | 2019 |
| CTI Clinical Trial and Consulting Services | For profit | 1 | 0 | 1 | 2020 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 0 | 1 | 2019 |
| Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2019 |
| University of Louisville | Academic/Hospital | 1 | 1 | 1 | 2019 |
5 organizations
Page 1 / 1